Disease relevance of Micromonospora

• Characterisation of aminoglycoside acetyltransferase-encoding genes of neomycin-producing Micromonospora chalcea and Streptomyces fradiae [1].
• A DNA fragment of 42 kb encompassing one of the mycinamicin II (Mm)-resistance-encoding genes, myrB, from a Mm-producing strain, Micromonospora griseorubida, was cloned in Escherichia coli using the cosmid vector pJB8 [2].
• Taxonomic analysis of four selected strains based on 16S rRNA similarity examinations revealed two Gordonia sp. strains, VH2 and Kb2, and one Mycobacterium fortuitum strain, NF4, belonging to the first group as well as one Micromonospora aurantiaca strain, W2b, belonging to the second group [3].
• Cell walls of a micromonospora strain (actinomycetales). III. Characterisation of a alpha-D-glucopyranosyl (1 leads to 6) -beta-D-glucopyranosyl (1 leads to 1 (6)) galactitol [4].
• Development of the Micromonospora carbonacea var. africana ATCC 39149 bacteriophage pMLP1 integrase for site-specific integration in Micromonospora spp [5].

High impact information on Micromonospora

• It is produced by Micromonospora megalomicea and differs from the well-known macrolide antibiotic erythromycin by the addition of a unique deoxyamino sugar, megosamine, to the C-6 hydroxyl [6].
• Production of antibiotics by biotransformation of 2,4,6/3,5-pentahydroxycyclohexanone and 2,4/3,5-tetrahydroxycyclohexanone by a deoxystreptamine-negative mutant of Micromonospora purpurea [7].
• Single crystals of neuraminidase from the bacterium Micromonospora viridifaciens were obtained using the hanging drop vapour diffusion method and polyethylene glycol as precipitant at pH 5.0 or 5 [8].
• The product of a gene that originated in Micromonospora purpurea (an actinomycete that produces gentamicin) gives resistance to kanamycin plus gentamicin by converting residue G-1405 to 7-methylguanosine [9].
• Dialyzed extracts of the gentamicin producer Micromonospora purpurea catalyze reactions which represent transaminations proposed for 2-deoxystreptamine biosynthesis [10].

Chemical compound and disease context of Micromonospora

• Ribosomal resistance in the gentamicin producer organism Micromonospora purpurea [11].
• The discovery of aminoglycoside 66-40C, a novel dimeric, unsaturated imine produced by Micromonospora inyoensis, afforded a versatile intermediate for the synthesis of a variety of sisomicin analogues modified at the 6' position [12].
• Sisomicin is a naturally occurring aminoglycoside antibiotic produced by Micromonospora inyoensis, while dibekacin and netilmicin are both semisynthetic aminoglycosides [13].
• A novel, highly efficient gene-cloning system in Micromonospora applied to the genetic analysis of fortimicin biosynthesis [14].
• Analysis of the self-defense gene (fmrO) of a fortimicin A (astromicin) producer, Micromonospora olivasterospora: comparison with other aminoglycoside-resistance-encoding genes [15].

Biological context of Micromonospora

• Contribution of the active site aspartic acid to catalysis in the bacterial neuraminidase from Micromonospora viridifaciens [16].
• Interestingly AN38-1, a non-producing mutant that had a defect in dehydroxylation of a precursor of FTM A, was complemented by the DNA fragment containing a neomycin resistance gene that had been cloned from a neomycin-producing strain (Micromonospora sp. FTM A non-producing strain) in the course of constructing the plasmid vector pMO116 [17].
• Gene clusters for the biosynthesis of kanamycin (Km) and gentamicin (Gm) were isolated from the genomic libraries of Streptomyces kanamyceticus and Micromonospora echinospora, respectively [18].
• Gene cluster in Micromonospora echinospora ATCC15835 for the biosynthesis of the gentamicin C complex [19].
• A non-rubber degrading mutant of the polyisoprene rubber degrading bacterium Micromonospora aurantiaca W2b lacking the capability to form halos on latex overlay agar plates was isolated after N-methyl-N-nitro-N-nitrosoguanidine mutagenesis [20].

Anatomical context of Micromonospora

• All species tested except Micromonospora globosa contained glycolate in an almost equimolar ratio to diaminopimelic acid in their cell walls [21].
• High yields of protoplasts from the 18-hr old mycelium of Trichoderma viride were obtained by using the lytic system, produced by Streptomyces venezuelae RA and Micromonospora chalcea grown on a synthetic medium containing laminarin and chitin, when 0.7 M MgSO4 or (NH4)2SO4 were used as osmotic stabilizers [22].

Gene context of Micromonospora

• The sgm gene was expressed in Micromonospora melanosporea, where its own promoter was active, and also in Escherichia coli under the control of the lacZ promoter [23].
• Plasmids pSPRH840 and pSPRH910, containing the pMLP1 att/int region, were introduced into Micromonospora spp. by conjugation from Escherichia coli [5].
• Isolation of L-2-(1-methylcyclopropyl)glycine from Micromonospora miyakonensis sp. nov. II. Isolation and characterization [24].
• Confirmation of the antibacterial mode of action of SB-219383, a novel tyrosyl tRNA synthetase inhibitor from a Micromonospora sp [25].
• MS-444, a new inhibitor of myosin light chain kinase from Micromonospora sp. KY7123 [26].

Analytical, diagnostic and therapeutic context of Micromonospora

• Radioimmunoassay of gentamicin in Micromonospora medium extracts [27].

References